Back to Agenda
Advancing Alzheimer’s Innovation: A Call to Action
Session Chair(s)
Meryl Comer
President; Founder, WomenAgainstAlzheimers
Geoffrey Beene Foundation Alzheimer's Initiative, United States
A visionary perspective on how industry and health authorities are working to help move towards a cure for Alzheimer's disease will be provided by a distinguished panel of experts in this inaugural forum. According to the World Alzheimer’s Report, currently 36 million have dementia worldwide, and the numbers will increase to 66 million people living with dementia by 2030 and 115 million by 2050. This forum will provide a comprehensive picture of the global impact of this disease and the progress towards earlier detection and meaningful therapeutic intervention. It will also look at key strategies that governments, advocacy groups, and industry are taking to elevate Alzheimer's disease on the global agenda to ensure that society is prepared to address the growing epidemic. This opening forum serves as the foundation for more focused sessions on the patient and caregiver perspectives, and on how to advance clinical development.
Learning Objective : Discuss the global impact of Alzheimer's and the progress towards earlier detection and meaningful therapeutic intervention; Discuss key strategies being taken to ensure that society is prepared to address the growing epidemic.
Speaker(s)
Latest From the G-8 Summit: Mobilizing Government, NGOs, and Industry to Prevent Alzheimer's Disease by 2025
George Vradenburg
USAgainstAlzheimer's, United States
Co-Founder/President
Research and Development: Searching for a Cure
Rudolph E. Tanzi, PhD
Massachusetts General Hospital, United States
Head, Genetics and Aging Research Unit; Prof, Neurology, Harvard Medical School
Can We Detect and Treat Alzheimer’s Disease a Decade Before Dementia: Why Would We Want To?
Reisa A. Sperling, MD
Brigham and Women's Hospital , United States
Director, Center for ALZ Rsrch & Treatment; Prof, Neurology, Harvard Medical
FDA Point of View
Nicholas A. Kozauer, MD
FDA, United States
Medical Officer, Office of New Drugs, CDER
The Growing Prevalence and Economic Impact of Alzheimer's Disease
Peter Neumann, DrSc
Tufts Medical Center, United States
Director, Center for Evaluation of Value and Risk in Health at ICRHPS
Have an account?